Krystal Biotech (KRYS) Net Equity Issued and Repurchased (2017 - 2023)

Krystal Biotech (KRYS) has 7 years of Net Equity Issued and Repurchased data on file, last reported at $10000.0 in Q4 2023.

• For the quarter ending Q4 2023, Net Equity Issued and Repurchased rose 100.25% year-over-year to $10000.0; the trailing twelve-month figure through Dec 2024 stood at -$112000.0 (down 100.07% YoY), and the FY2023 full-year result was $159.7 million, up 451.01% from the prior year.
• Net Equity Issued and Repurchased climbed to $10000.0 in Q4 2023, from -$122000.0 in the prior quarter.
• In the past five years, Net Equity Issued and Repurchased ranged from a high of $202.1 million in Q4 2021 to a low of -$3.9 million in Q4 2022.
• A 5-year average of $38.5 million and a median of $1.1 million in 2020 frame the typical range for Net Equity Issued and Repurchased.
• Across the five-year window, Net Equity Issued and Repurchased soared 2350375.0% in 2019 and sank 105.75% in 2023, its largest moves.
• Tracing KRYS's Net Equity Issued and Repurchased over 5 years: stood at $299000.0 in 2019, then jumped by 157.53% to $770000.0 in 2020, then soared by 26143.12% to $202.1 million in 2021, then sank by 101.95% to -$3.9 million in 2022, then jumped by 100.25% to $10000.0 in 2023.
• Business Quant data shows KRYS's Net Equity Issued and Repurchased at $10000.0 in Q4 2023, -$122000.0 in Q3 2023, and $157.6 million in Q2 2023.